Skip to main content
Top
Published in: Journal of Clinical Immunology 4/2006

01-07-2006

The Effects of Tacrolimus Ointment on Regulatory T Lymphocytes in Atopic Dermatitis

Authors: Marzia Caproni, Daniele Torchia, Emiliano Antiga, Walter Volpi, Elena Del Bianco, Paolo Fabbri

Published in: Journal of Clinical Immunology | Issue 4/2006

Login to get access

Abstract

Only very recently studies were conducted in order to evaluate the impact of regulatory T (Treg) cells in the pathophysiology of atopic dermatitis (AD). Nine adult patients with moderate-to-severe AD in riacutization period of a chronic disease were given tacrolimus ointment, while seven hydrocortisone butyrate ointment, that served as controls. We performed lesional-skin biopsies before and after treatment, that were stained immunohistochemically with monoclonal antibodies to CD4, CD25, forkhead/winged helix transcription factor (FoxP3), interleukin (IL)-10 and transforming growth factor (TGF)-β. CD4+ cells were significantly reduced in post-treatment series. Tacrolimus treatment achieved a significant reduction of CD25+ cells. FoxP3+ cells were present in untreated AD lesions. Both treatments did not significantly modify the number of FoxP3+ cells. The number of IL-10+ cells increased in post-treatment series. Tacrolimus enhanced the production of TGF-β, while hydrocortisone did not.
Restoration of TGF-β-producing Treg cells may represent another important pharmacodynamic effect of tacrolimus on AD.
Literature
1.
go back to reference Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid Q: New insights into atopic dermatitis. J Clin Invest 113:651–657, 2004PubMed Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid Q: New insights into atopic dermatitis. J Clin Invest 113:651–657, 2004PubMed
2.
go back to reference Bluestone JA, Abbas AK: Natural versus adaptive regulatory T cells. Nat Rev Immunol 3:253–257, 2003PubMedCrossRef Bluestone JA, Abbas AK: Natural versus adaptive regulatory T cells. Nat Rev Immunol 3:253–257, 2003PubMedCrossRef
3.
go back to reference Goleva E, Cardona ID, Ou LS, Leung DY: Factors that regulate naturally occurring T regulatory cell-mediated suppression. J Allergy Clin Immunol 116:1094–1100, 2005PubMedCrossRef Goleva E, Cardona ID, Ou LS, Leung DY: Factors that regulate naturally occurring T regulatory cell-mediated suppression. J Allergy Clin Immunol 116:1094–1100, 2005PubMedCrossRef
4.
go back to reference Taylor A, Verhagen J, Akdis CA, Akdis M: T regulatory cells and allergy. Microbes and Infection 7:1049–1055, 2005PubMedCrossRef Taylor A, Verhagen J, Akdis CA, Akdis M: T regulatory cells and allergy. Microbes and Infection 7:1049–1055, 2005PubMedCrossRef
5.
go back to reference Ou LS, Goleva E, Hall MS, Leung DY: T regulatory cells in atopic dermatitis and subversion of their activity by superantigens. J Allergy Clin Immunol 113:756–763, 2004PubMedCrossRef Ou LS, Goleva E, Hall MS, Leung DY: T regulatory cells in atopic dermatitis and subversion of their activity by superantigens. J Allergy Clin Immunol 113:756–763, 2004PubMedCrossRef
6.
go back to reference Vukmanovic-Stejic M, McQuaid A, Birch KE, Reed JR, Macgregor C, Rustin MHA, Akbar AN: Relative impact of CD4+CD25+ regulatory T cells and tacrolimus on inhibition of T-cell proliferation in patients with atopic dermatitis. Br J Dermatol 153:750–757, 2005PubMedCrossRef Vukmanovic-Stejic M, McQuaid A, Birch KE, Reed JR, Macgregor C, Rustin MHA, Akbar AN: Relative impact of CD4+CD25+ regulatory T cells and tacrolimus on inhibition of T-cell proliferation in patients with atopic dermatitis. Br J Dermatol 153:750–757, 2005PubMedCrossRef
7.
go back to reference Verhagen J, Akdis M, Traidl-Hoffmann C, Schmid-Grendelmeier P, Hijnen D, Knol EF, Behrendt H, Blaser K, Akdis CA: Absence of T-regulatory cell expression and function in atopic dermatitis skin. J Allergy Clin Immunol 117:176–183, 2006PubMedCrossRef Verhagen J, Akdis M, Traidl-Hoffmann C, Schmid-Grendelmeier P, Hijnen D, Knol EF, Behrendt H, Blaser K, Akdis CA: Absence of T-regulatory cell expression and function in atopic dermatitis skin. J Allergy Clin Immunol 117:176–183, 2006PubMedCrossRef
8.
go back to reference Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC: Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trias. Br Med J 330:516–522, 2005CrossRef Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC: Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trias. Br Med J 330:516–522, 2005CrossRef
9.
go back to reference Alomar A, Berth-Jones J, Bos JD, Giannetti A, Reitamo S, Ruzicka T, Stalder JF, Thestrup-Pedersen K, European Working Group on Atopic Dermatitis: The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol 151(Suppl 70):3–27, 2004PubMedCrossRef Alomar A, Berth-Jones J, Bos JD, Giannetti A, Reitamo S, Ruzicka T, Stalder JF, Thestrup-Pedersen K, European Working Group on Atopic Dermatitis: The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol 151(Suppl 70):3–27, 2004PubMedCrossRef
10.
go back to reference Baan CC, van der Mast BJ, Klepper M, Mol WM, Peeters AM, Korevaar SS, Balk AK, Weimar W: Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 80:110–117, 2005PubMedCrossRef Baan CC, van der Mast BJ, Klepper M, Mol WM, Peeters AM, Korevaar SS, Balk AK, Weimar W: Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 80:110–117, 2005PubMedCrossRef
11.
go back to reference Hanifin JM, Rajka G: Diagnostic features of atopic dermatitis: Acta Derm. Venereol (Stockh) Suppl 92:44–47, 1980 Hanifin JM, Rajka G: Diagnostic features of atopic dermatitis: Acta Derm. Venereol (Stockh) Suppl 92:44–47, 1980
12.
go back to reference Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A: Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 195:10–19, 1997PubMedCrossRef Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A: Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 195:10–19, 1997PubMedCrossRef
13.
go back to reference Caproni M, Giomi B, Volpi W, Melani L, Schincaglia E, Macchia D, Manfredi M, D’Agata A, Fabbri P: Chronic idiopathic urticaria: infiltrating cells and related cytokines in autologous serum-induced wheals. Clin Immunol 114:284–292, 2005PubMedCrossRef Caproni M, Giomi B, Volpi W, Melani L, Schincaglia E, Macchia D, Manfredi M, D’Agata A, Fabbri P: Chronic idiopathic urticaria: infiltrating cells and related cytokines in autologous serum-induced wheals. Clin Immunol 114:284–292, 2005PubMedCrossRef
14.
go back to reference Leung DY: Atopic dermatitis: new insights and opportunities for therapeutic interventions. J Allergy Clin Immunol 105:860–876, 2000PubMedCrossRef Leung DY: Atopic dermatitis: new insights and opportunities for therapeutic interventions. J Allergy Clin Immunol 105:860–876, 2000PubMedCrossRef
15.
go back to reference Simon D, Vassina E, Yousefi S, Kozlowski E, Braathen LR, Simon HU: Reduced dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment. J Allergy Clin Immunol 114:887–895, 2004PubMedCrossRef Simon D, Vassina E, Yousefi S, Kozlowski E, Braathen LR, Simon HU: Reduced dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment. J Allergy Clin Immunol 114:887–895, 2004PubMedCrossRef
16.
go back to reference Wollenberg A, Sharma S, von Bubnoff D, Geiger E, Haberstok J, Bieber T: Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol 107:519–525, 2001PubMedCrossRef Wollenberg A, Sharma S, von Bubnoff D, Geiger E, Haberstok J, Bieber T: Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol 107:519–525, 2001PubMedCrossRef
17.
go back to reference Akdis M, Akdis CA, Weigl L, Disch R, Blaser K: Skin-homing, CLA+ memory T cells are activated in atopic dermatitis and regulate IgE by an IL-13-dominated cytokine pattern: IgG4 counter-regulation by CLA- memory T cells. J Immunol 159:4611–4619, 1997PubMed Akdis M, Akdis CA, Weigl L, Disch R, Blaser K: Skin-homing, CLA+ memory T cells are activated in atopic dermatitis and regulate IgE by an IL-13-dominated cytokine pattern: IgG4 counter-regulation by CLA- memory T cells. J Immunol 159:4611–4619, 1997PubMed
18.
go back to reference Knoechel B, Lohr J, Kahn E, Bluestone JA, Abbas AK: Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med 202:1375–1386, 2005PubMedCrossRef Knoechel B, Lohr J, Kahn E, Bluestone JA, Abbas AK: Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med 202:1375–1386, 2005PubMedCrossRef
19.
go back to reference Wraith DC: Role of interleukin-10 in the induction and function of natural and antigen-induced regulatory T cells. J Autoimmun 20:273–275, 2003PubMedCrossRef Wraith DC: Role of interleukin-10 in the induction and function of natural and antigen-induced regulatory T cells. J Autoimmun 20:273–275, 2003PubMedCrossRef
20.
go back to reference Simon D, Vassina E, Yousefi S, Braathen LR, Simon HU: Inflammatory cell numbers and cytokine expression in atopic dermatitis after topical pimecrolimus treatment. Allergy 60:944–951, 2005PubMedCrossRef Simon D, Vassina E, Yousefi S, Braathen LR, Simon HU: Inflammatory cell numbers and cytokine expression in atopic dermatitis after topical pimecrolimus treatment. Allergy 60:944–951, 2005PubMedCrossRef
21.
go back to reference Peek EJ, Richards DF, Faith A, Lavender P, Lee TH, Corrigan CJ, Havrylowicz CM: Interleukin-10-secreting “regulatory” T cells induced by glucocorticoids and beta2-agonist. Am J Respir Cell Mol Biol 33:105–111, 2005PubMedCrossRef Peek EJ, Richards DF, Faith A, Lavender P, Lee TH, Corrigan CJ, Havrylowicz CM: Interleukin-10-secreting “regulatory” T cells induced by glucocorticoids and beta2-agonist. Am J Respir Cell Mol Biol 33:105–111, 2005PubMedCrossRef
22.
go back to reference Aoki CA, Borchers AT, Li M, Flavell RA, Bowlus CL, Ansari AA, Gershwin ME: Transforming growth factor beta (TGF-beta) and autoimmunity.Autoimmun Rev 4:450–459, 2005PubMedCrossRef Aoki CA, Borchers AT, Li M, Flavell RA, Bowlus CL, Ansari AA, Gershwin ME: Transforming growth factor beta (TGF-beta) and autoimmunity.Autoimmun Rev 4:450–459, 2005PubMedCrossRef
23.
go back to reference Arkwright PD, Chase JM, Babbage S, Pravica V, David TJ, Hutchinson IV: Atopic dermatitis is associated with a low-producer transforming growth factor beta(1) cytokine genotype. J Allergy Clin Immunol 108:281–284, 2001PubMedCrossRef Arkwright PD, Chase JM, Babbage S, Pravica V, David TJ, Hutchinson IV: Atopic dermatitis is associated with a low-producer transforming growth factor beta(1) cytokine genotype. J Allergy Clin Immunol 108:281–284, 2001PubMedCrossRef
24.
go back to reference Lee HJ, Lee HP, Ha SJ, Byun DG, Kim JW: Spontaneous expression of mRNA for IL-10, GM-CSF, TGF-beta, TGF-alpha, and IL-6 in peripheral blood mononuclear cells from atopic dermatitis. Ann Allergy Asthma Immunol 84:553–558, 2000PubMedCrossRef Lee HJ, Lee HP, Ha SJ, Byun DG, Kim JW: Spontaneous expression of mRNA for IL-10, GM-CSF, TGF-beta, TGF-alpha, and IL-6 in peripheral blood mononuclear cells from atopic dermatitis. Ann Allergy Asthma Immunol 84:553–558, 2000PubMedCrossRef
25.
go back to reference Lan CC, Kao YH, Huang SM, Yu HS, Chen GS: FK506 independently upregulates transforming growth factor beta and downregulates inducible nitric oxide synthase in cultured human keratinocytes: possible mechanisms of how tacrolimus ointment interacts with atopic skin. Br J Dermatol 151:679–684, 2004PubMedCrossRef Lan CC, Kao YH, Huang SM, Yu HS, Chen GS: FK506 independently upregulates transforming growth factor beta and downregulates inducible nitric oxide synthase in cultured human keratinocytes: possible mechanisms of how tacrolimus ointment interacts with atopic skin. Br J Dermatol 151:679–684, 2004PubMedCrossRef
26.
go back to reference Khanna AK: The immunosuppressive agent tacrolimus induces p21WAF/CIP1WAF1/CIP1 via TGF-beta secretion. Biochem Biophys Res Commun 303:266–272, 2003PubMedCrossRef Khanna AK: The immunosuppressive agent tacrolimus induces p21WAF/CIP1WAF1/CIP1 via TGF-beta secretion. Biochem Biophys Res Commun 303:266–272, 2003PubMedCrossRef
Metadata
Title
The Effects of Tacrolimus Ointment on Regulatory T Lymphocytes in Atopic Dermatitis
Authors
Marzia Caproni
Daniele Torchia
Emiliano Antiga
Walter Volpi
Elena Del Bianco
Paolo Fabbri
Publication date
01-07-2006
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 4/2006
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-006-9034-2

Other articles of this Issue 4/2006

Journal of Clinical Immunology 4/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.